NASDAQ:TBPH - Theravance Biopharma Price Target & Analyst Ratings

$22.81
-0.12 (-0.52 %)
(As of 09/16/2019 10:14 AM ET)
Today's Range
$22.75
Now: $22.81
$23.36
50-Day Range
$18.94
MA: $20.97
$24.08
52-Week Range
$15.18
Now: $22.81
$35.48
Volume6,783 shs
Average Volume202,184 shs
Market Capitalization$1.29 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.72

Analyst Ratings

Theravance Biopharma (NASDAQ:TBPH) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Theravance Biopharma in the last 12 months. Their average twelve-month price target is $49.3333, suggesting that the stock has a possible upside of 116.28%. The high price target for TBPH is $55.00 and the low price target for TBPH is $38.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $49.3333$49.3333$47.00$47.00
Price Target Upside: 116.28% upside131.39% upside98.40% upside89.59% upside

Theravance Biopharma (NASDAQ:TBPH) Consensus Price Target History

Theravance Biopharma (NASDAQ:TBPH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/9/2019Piper Jaffray CompaniesReiterated RatingBuyLow
8/16/2019Cantor FitzgeraldSet Price TargetBuy$55.00Low
11/7/2018Leerink SwannSet Price TargetBuy$38.00Medium
8/1/2018Needham & Company LLCReiterated RatingBuy$40.00Low
11/1/2017Robert W. BairdReiterated RatingSell$22.00N/A
(Data available from 9/16/2017 forward)
This page was last updated on 9/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel